» Articles » PMID: 38543819

Clinical Manifestations of Infections with the Omicron Sub-Lineages BA.1, BA.2, and BA.5: A Retrospective Follow-Up Analysis of Public Health Data from Mecklenburg-Western Pomerania, Germany

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2024 Mar 28
PMID 38543819
Authors
Affiliations
Soon will be listed here.
Abstract

The Omicron variants BA.1, BA.2, and BA.5 caused several waves of SARS-CoV-2 in Germany in 2022. In this comparative study, public health data on SARS-CoV-2 infections from Mecklenburg-Western Pomerania, Germany, between January and October 2022 were examined retrospectively using Pearson's chi-squared tests and Fisher's exact tests for testing for statistical significance. Compared to BA.5 infections, BA.1 and BA.2 infections affected younger individuals aged up to 19 years significantly more often, whereas BA.5 infections occurred significantly more frequently in patients between 40 and 59 years of age when compared to BA.1 and BA.2. Infections with all three variants predominantly caused flu-like symptoms; nevertheless, there were significant differences between the reported symptoms of BA.1, BA.2, and BA.5 infections. Especially, the symptoms of 'fever', 'severe feeling of sickness', 'loss of taste', and 'loss of smell' were significantly more often present in patients with BA.5 infections compared to BA.1 and BA.2 cases. Additionally, BA.2 and BA.5 cases reported significantly more often the symptoms of 'runny nose' and 'cough' than BA.1-infected cases. Our findings indicate remarkable differences in the clinical presentations among the sub-lineages, especially in BA.5 infections. Furthermore, the study demonstrates a powerful tool to link epidemiological data with genetic data in order to investigate their potential impact on public health.

Citing Articles

4D-DIA Proteomics Uncovers New Insights into Host Salivary Response Following SARS-CoV-2 Omicron Infection.

de Lima I, Cataldi T, Brites C, Labate M, Vaz S, Deminco F J Proteome Res. 2025; 24(2):499-514.

PMID: 39803891 PMC: 11812090. DOI: 10.1021/acs.jproteome.4c00630.


Mass Spectrometry-Based Metabolomics Reveals a Salivary Signature for Low-Severity COVID-19.

de Lima I, Silva A, Brites C, Angelo da Silva Miyaguti N, Raposo Passos Mansoldo F, Vaz Nunes S Int J Mol Sci. 2024; 25(22).

PMID: 39595969 PMC: 11593410. DOI: 10.3390/ijms252211899.


Cross-Section of Neurological Manifestations Among SARS-CoV-2 Omicron Subvariants-Single-Center Study.

Jachman-Kapulka J, Zinczuk A, Simon K, Rorat M Brain Sci. 2024; 14(11).

PMID: 39595924 PMC: 11591697. DOI: 10.3390/brainsci14111161.


Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model.

Wongnak R, Brindha S, Oba M, Yoshizue T, Islam M, Islam M Molecules. 2024; 29(11).

PMID: 38893549 PMC: 11173568. DOI: 10.3390/molecules29112676.

References
1.
Fonager J, Bennedbaek M, Bager P, Wohlfahrt J, Ellegaard K, Ingham A . Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Euro Surveill. 2022; 27(10). PMC: 8915403. DOI: 10.2807/1560-7917.ES.2022.27.10.2200181. View

2.
Ballouz T, Menges D, Kaufmann M, Amati R, Frei A, von Wyl V . Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts. PLoS One. 2023; 18(2):e0281429. PMC: 9946205. DOI: 10.1371/journal.pone.0281429. View

3.
Sievers C, Zacher B, Ullrich A, Huska M, Fuchs S, Buda S . SARS-CoV-2 Omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022. Euro Surveill. 2022; 27(22). PMC: 9164675. DOI: 10.2807/1560-7917.ES.2022.27.22.2200396. View

4.
Menni C, Valdes A, Polidori L, Antonelli M, Penamakuri S, Nogal A . Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022; 399(10335):1618-1624. PMC: 8989396. DOI: 10.1016/S0140-6736(22)00327-0. View

5.
Sass J, Bartschke A, Lehne M, Essenwanger A, Rinaldi E, Rudolph S . The German Corona Consensus Dataset (GECCO): a standardized dataset for COVID-19 research in university medicine and beyond. BMC Med Inform Decis Mak. 2020; 20(1):341. PMC: 7751265. DOI: 10.1186/s12911-020-01374-w. View